Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.34 |
| ▸ | MELK | Q14680 | 1/20 | 0.34 |
| ▸ | STK24 | Q9Y6E0 | 1/20 | 0.34 |
| ▸ | ERCC5 | P28715 | 2/20 | 0.34 |
| ▸ | FEN1 | P39748 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 2/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL379713 | 0.78 | PARP1 (0.40) | JAK2RPS6KA3MELKSTK24PARP1 | |
| SCHEMBL26013119 | 0.75 | CHEK1 (0.35) | JAK2RPS6KA3MELKSTK24GAA | |
| SCHEMBL26013738 | 0.72 | KDM4E (0.48) | GAANPC1 | |
| SCHEMBL26013116 | 0.72 | PDPK1 (0.37) | PDPK1JAK2RPS6KA3MELKSTK24 | |
| SCHEMBL4426300 | 0.71 | CYP2A6 (0.46) | ERCC5FEN1CYP2A6 | |
| SCHEMBL5044315 | 0.71 | — | — | |
| SCHEMBL13764548 | 0.71 | PDPK1 (0.44) | PDPK1ERCC5FEN1GAAPARP1 | |
| SCHEMBL14912198 | 0.70 | MAPT (0.53) | GAANPC1RAB9A | |
| SCHEMBL24757248 | 0.69 | JAK2 (0.42) | PDPK1JAK2RPS6KA3MELKSTK24 | |
| SCHEMBL24322188 | 0.69 | PDPK1 (0.47) | PDPK1JAK2PARP1CYP2A6RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256154-A1 | 4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid amides | LUK KIN-CHUN | 2005-11-17 | — | — | US | claimed |
| EP-1926737-B1 | 4-AMINO-THIENO[3,2-C]PYRIDINE-7-CARBOXYLIC ACID DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-03-15 | — | — | EP | disclosed |
| EP-1926737-B1 | 4-AMINO-THIENO[3,2-C]PYRIDINE-7-CARBOXYLIC ACID DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-03-15 | — | — | EP | disclosed |
| US-7994321-B2 | Substituted thieno[3,2-C]pyridine-7-carboxylic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-08-09 | — | — | US | disclosed |
| US-7994321-B2 | Substituted thieno[3,2-C]pyridine-7-carboxylic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-08-09 | — | — | US | disclosed |
| US-20110071147-A1 | 4-AMINO-THIENO[3,2-C]PYRIDINE-7-CARBOXYLIC ACID AMIDES | LUK KIN-CHUN | 2011-03-24 | — | — | US | disclosed |
| US-20110071147-A1 | 4-AMINO-THIENO[3,2-C]PYRIDINE-7-CARBOXYLIC ACID AMIDES | LUK KIN-CHUN | 2011-03-24 | — | — | US | disclosed |
| US-7635695-B2 | Antiinflammation agents | AMGEN INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-7635695-B2 | Antiinflammation agents | AMGEN INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-7635695-B2 | Antiinflammation agents | AMGEN INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-20070060607-A1 | 4-amino-thieno[3,2-c] pyridine-7-carboxylic acid derivatives | BARTKOVITZ DAVID J | 2007-03-15 | — | — | US | disclosed |
| US-20070060607-A1 | 4-amino-thieno[3,2-c] pyridine-7-carboxylic acid derivatives | BARTKOVITZ DAVID J | 2007-03-15 | — | — | US | disclosed |
| WO-2007019884-A1 | NOVEL 4-AMINO-THIENO[3,2-C]PYRIDINE-7-CARBOXYLIC ACID AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-22 | — | — | WO | disclosed |
| WO-2007019884-A1 | NOVEL 4-AMINO-THIENO[3,2-C]PYRIDINE-7-CARBOXYLIC ACID AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-22 | — | — | WO | disclosed |
| US-20070032512-A1 | 6,6-Bicyclic ring substituted sulfur containing heterobicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC., | 2007-02-08 | — | — | US | disclosed |
| EP-1556053-A4 | ANTIINFLAMMATION AGENTS | AMGEN INC (US) | 2006-04-19 | — | — | EP | disclosed |
| US-20050256154-A1 | 4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid amides | LUK KIN-CHUN | 2005-11-17 | — | — | US | disclosed |
| EP-1556053-A1 | ANTIINFLAMMATION AGENTS | Amgen Inc. (US) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004041285-A1 | ANTIINFLAMMATION AGENTS | AMGEN INC. (US) | 2004-05-21 | — | — | WO | disclosed |
| US-20040097485-A1 | Antiinflammation agents | TULARIK INC. | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256154-A1 | 4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid amides | FGFR3, FGFR4, FGFR1 | PDPK1 386/4885JAK2 77/4885RPS6KA3 345/4885 |
| US-20070060607-A1 | 4-amino-thieno[3,2-c] pyridine-7-carboxylic acid derivatives | BRAF, RAF1, MAP3K7 | PDPK1 108/4885JAK2 96/4885RPS6KA3 87/4885 |
| US-20070032512-A1 | 6,6-Bicyclic ring substituted sulfur containing heterobicyclic protein kinase inhibitors | IGF1R, BRCA1, MAP2K6 | PDPK1 94/4885JAK2 67/4885RPS6KA3 29/4885 |
| US-20110071147-A1 | 4-AMINO-THIENO[3,2-C]PYRIDINE-7-CARBOXYLIC ACID AMIDES | FGFR3, FGFR4, FGFR1 | PDPK1 386/4885JAK2 77/4885RPS6KA3 345/4885 |
| US-20040097485-A1 | Antiinflammation agents | TNF, NFATC1, NFKBIA | PDPK1 948/4885JAK2 1101/4885RPS6KA3 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.